Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05499611
Other study ID # CHUBX 2022/28
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 27, 2023
Est. completion date January 2024

Study information

Verified date October 2023
Source University Hospital, Bordeaux
Contact Audrey BIDET
Phone +335 57 62 32 85
Email audrey.bidet@chu-bordeaux.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

A retrospective study using a new technology will be performed: the Optical Genome Mapping (OGM) on acute myelogenous leukemia (AML) samples stored at the CRB-Cancer of the Bordeaux University Hospital and annotated in the DATAML clinical database. The main objective is to estimate the proportion of AML patients for whom OGM detects at least one additional abnormality compared to conventional techniques. This study will constitute an important step in the validation of COA as a reference technique for cytogenetic analysis in AML, replacing the classical techniques, and could also constitute a first argument for redesigning the prognostic classification of AML.


Description:

In AML prognostic classifications, such as the ELN 2017 classification, which are used to guide treatment choices in the majority of protocols, rely heavily on genetic abnormalities. The Optical Genome Mapping (OGM) is a new technology that combines in one and the same technique the results of karyotype, FISH and SNP-Array, the latter being very little used in current practice in AML. OGM with greater sensitivity and a better resolution than the usual techniques should therefore allow us to identify more abnormalities than conventional cytogenetics; we would then like to determine whether these additional abnormalities have a prognostic impact, i.e., whether they lead to reclassification of patients initially classified as "favorable" or "intermediate" into the "unfavorable" prognostic category, with therapeutic consequences. A retrospective study using the OGM is will be performed on samples stored at the CRB-Cancer of the Bordeaux University Hospital and annotated in the DATAML clinical database. In an original way, the focus will be on AML patients in whom 1 to 3 chromosomal abnormalities (non-recurrent WHO, not related to an unfavourable prognosis) have already been demonstrated by classical techniques, making the hypothesis that it is in this population that we would more easily have patients who could fall into the definition of the complex karyotype and thus into the unfavourable risk category. OGM should therefore reveal a greater number of abnormalities which would allow a better definition of karyotypes with abnormalities, the number of complex and/or monosomal karyotypes and a better stratification of the prognosis of these patients with AML. This is an applied translational research study based on innovative technology that will define the place of OGM over current techniques used in the initial management of AML patients, and it may well become the new standard for cytogenetic analysis of AML in the coming years.


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date January 2024
Est. primary completion date December 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Patients = 18 years and = 65 years of age who have been treated with intensive chemotherapy - Diagnosis of AML (with a minimum follow-up of 24 months) - Presence of samples included in CRB-K in the AML collection - Cytogenetic data available: karyotype with 1-3 abnormalities present in one or more clones, excluding recurrent WHO abnormalities (t(8;21), inv(16) or t(16;16), t(9;11), t(v;11)(v;q23. 3), t(6;9), inv(3) or t(3;3) and t(9;22)) or assigned by itself to an unfavorable prognosis: -5 or del(5q); -7; -17/abn(17p). - Molecular data available for the following genes: ASXL1, CEBPA, FLT3-ITD, NPM1, RUNX1 and TP53 (the list of genes of interest may be adapted according to the upcoming ELN 2022 classification) Exclusion Criteria: - Samples not included in the CRB-K (lack of consent, insufficient material...) - Karyotype with one of the following abnormalities: (t(8;21), inv(16) or t(16;16), t(9;11), t(v;11)(v;q23.3), t(6;9), inv(3) or t(3;3), and t(9;22)) or associated with an unfavorable prognosis on its own: -5 or del(5q); -7; -17/abn(17p) - Karyotype without clonal abnormality

Study Design


Locations

Country Name City State
France CHU de Bordeaux, service Hématologie Biologique Bordeaux

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Bordeaux

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of patients with more abnormalities detected by OGM than by conventional cytogenetics At baseline
Secondary Average number of additional abnormalities detected by OGM compared to conventional techniques At baseline
Secondary Proportion of patients reclassified as complex and/or monosomal karyotype according to current ELN definitions At baseline
Secondary Proportion of patients for whom a change in therapeutic management could have been proposed From baseline to Month 36
Secondary Comparison of overall survival and event-free survival curves of patients reclassified to the unfavorable group to those of the intermediate and unfavorable groups in a historical cohort From baseline to Month 36
Secondary Interobserver reproducibility for interpretation of OGM results (Fleiss Kappa coefficient) At baseline
See also
  Status Clinical Trial Phase
Completed NCT04452604 - Multicentric Registry of Patients With Acute Leukemia Infected by COVID-19
Completed NCT01041040 - LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML) Phase 4
Completed NCT00552825 - Pulmonary Function at Presentation and Follow-up in Hemato-Oncology 3-7 Years Old Children N/A
Recruiting NCT01966497 - Observational Study of Patients Older Than 60 Years With Acute Myeloblastic Leukemia N/A
Active, not recruiting NCT01457885 - Multi-center Study of Myeloablative Allo Stem Cell Transplant for Non-remission AML Using CloBu4 Regimen Phase 2
Completed NCT04082286 - Yttrium-90 Anti CD66 Monoclonal Antibody in Childhood Relapsed/Refractory Leukaemia Phase 1
Completed NCT01611116 - Study With Temsirolimus Added to Standard Chemotherapy for Patients Over 60 Years With Acute Myeloblastic Leukemia Phase 2
Completed NCT00504920 - Symptom-Related Cytokines in Acute Myeloblastic Leukemia and Myelodysplastic Syndrome Patients N/A
Completed NCT00354120 - Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant Phase 2/Phase 3
Completed NCT03280290 - Transplant T CD4+ CCR7+ In Hematopoietic Stem Cells Allograft N/A
Completed NCT01435343 - Treatment of Relapsed or Refractory Acute Myeloblastic Leukemia Phase 1/Phase 2
Completed NCT00487448 - SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia Phase 4
Completed NCT00390715 - Treatment of Acute Myeloblastic Leukemia in Younger Patients Phase 4
Completed NCT05696457 - Effects of Music Therapy in Controlling Symptoms in Patients With AML and Undergoing HSCT N/A
Recruiting NCT01296178 - PETHEMA-LMA10: Treatment of Acute Myeloblastic Leukemia (AML) in Patients Less Than or Equal to 65 Years N/A
Active, not recruiting NCT01307241 - RFC and MTHFR SNPs & hENT1- dCK Expression as Prognostic Factors in ALL & hENT1- dCK Expression as Prognostic Factors in AML N/A
Completed NCT00435864 - Natural Killer Index From Hematopoietic Stem Cell Graft N/A